Navigation Links
New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
Date:6/3/2010

udy is still ongoing, the researchers found that MIPI did not identify the three distinct staging categories with respect to patients' overall survival or progression-free survival, the primary endpoints for this study. Dr. Mato and colleagues are collaborating with another center to verify their results. Future work will focus on identifying molecular markers for failure in mantle cell lymphoma patients treated with dose-intensive regimens.

Vorinostat proves safe and tolerable for treating various cancers. (Abstract number e13600; publication-only abstract)

David S. Siegel, M.D., Ph.D., Co-Chief, Multiple Myeloma at the John Theurer Cancer Center and colleagues will present their analyses of safety and tolerability data from Phase I and II studies of vorinostat. Vorinostat is a medication that is FDA approved to treat skin problems related to cutaneous T-cell lymphoma when other treatments have not been effective. It is a histone deacetylase (HDAC) inhibitor, the first in a class of drugs that regulate enzymes involved in cell signaling. Vorinostat is also being investigated as a treatment option for a range of other solid and hematologic malignancies.

The researchers looked at safety and tolerability data from patients in phase I and II Merck-sponsored clinical trials who received vorinostat as a single (monotherapy) or combination therapy for a variety of cancers. Data from these unblinded trials showed that vorinostat has an acceptable safety and tolerability profile when given as monotherapy, or more commonly in a combination regimen, for patients with refractory metastatic cancer.

Denileukin diftitox shows promise for newly diagnosed T-cell lymphoma patients (the CONCEPT trial). (Abstract number 8045; poster session, June 4, 5:00 –

SOURCE John Theurer Cancer Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
2. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand
4. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
5. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
9. Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... -- Research and Markets  has announced ... Report 2014" report to their offering. ... Palmitic Acid Industry Report 2014 is a professional and ... palmitic acid industry. The report provides a ... and industry chain structure. The palmitic acid market analysis ...
(Date:11/27/2014)... Spartan Bioscience today announced that it has received ... regulatory approval for its Spartan RX CYP2C19 System ... 60 minutes from a non-invasive cheek swab. , The ... to determine therapeutic strategies for drugs metabolized by the ... world’s most commonly prescribed drugs such as Plavix® (clopidogrel), ...
(Date:11/27/2014)... 2014 First articles published ... Elsevier , a world-leading provider of scientific, ... to announce the launch of a new journal: ... The launch of Extreme Mechanics Letters ... forefront of applied sciences such as micro and nanotechnologies, ...
(Date:11/27/2014)... EDINBURGH , November 27, 2014 ... on revolutionising the management of tooth decay, today ... study of its Calcivis® Caries Activity Imaging System. ... is a sophisticated medical device and consumable combination ... dental caries (tooth decay). It involves a unique, ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3
... 2011 Sigma-Aldrich® (NASDAQ: SIAL ) ... Directors declared a quarterly cash dividend of $.18 per share. ... of record on December 1, 2011. The Board ... the Company,s repurchase authorization.  This action brings the total authorization ...
... Star Line Group , U.S. Advisors ... reinsurance program in response to the final regulations published recently ... "We recognize the unique requirements of organizations that want ... need to moderate their downside risk in an affordable fashion," ...
... Nov. 8, 2011 ACCESS PHARMACEUTICALS, INC. ... proprietary drug-delivery platforms to develop treatments in areas of ... it has entered into an agreement with a major ... CobOral technology for the targeted delivery of RNAi therapeutics. ...
Cached Biology Technology:Sigma-Aldrich (NASDAQ: SIAL) Declares Quarterly Dividend. 2New ACO Reinsurance Program Launched by Star Line Group, U.S. Advisors and Ascendent Care 2Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery 2Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery 3
(Date:11/4/2014)... VILNIUS, Lithuania , Nov. 4, 2014 /PRNewswire/ ... identification technologies, today announced that the latest version ... place in the Ongoing MINEX evaluation ... interoperability of fingerprint algorithms using the INCITS 378 ... a mandatory requirement in public tenders in ...
(Date:11/3/2014)... A University of Colorado Cancer Center study ... Academy of Sciences describes the activity of a ... Interleukin 37 or IL-37. It has been known to ... in the adaptive immune system: IL-37 inhibits the ability ... antigens. , "Knowing this mechanism that underlies IL-37,s effect ...
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... discovery by Monash University scientists could see humble cotton ... devices capable of detecting diseases such as kidney failure ... have used ordinary cotton thread and sewing needles to ... is the size of a postage stamp. Microfluidic ...
... look identicalnot to mention drabto the human eye. But that,s ... essentially colorblind. A new study published online on February 25th ... that the fish can easily tell one species from another ... on their faces. Although scientists have long known that ...
... that a microbe called Trichodesmium , a member of ... budget. New research results reported on-line today in a ... may have to share its nitrogen-fixing throne: two others ... UCYN-A and Crocosphaera watsonii , are also abundant in ...
Cached Biology News:How long is a piece of thread? Long enough to save a life 2Fish can recognize a face based on UV pattern alone 2More than 1: Long-reigning microbe controlling ocean nitrogen shares the throne 2
... Tracker Intracellular Localization Kit provides a straight ... siRNA, of your design, in an efficient ... experiments. Subcellular localization and functional inhibition of ... introduction of the labeled siRNA into mammalian ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Invasion Assay is designed to determine the ... a significant barrier to invasion or to ... a convenient, high-throughput, 96-well format. The 8 ... types of adherent cells such as epithelial, ...
... GrabIt™ Kits are designed for the study ... a pull-down method. Proteins that interact with ... fusion proteins are copurified using affinity resins ... retained on a spin filter. The complexes ...
Biology Products: